N. Leonard Dunne E. Muller Muller Bhalodi aureus VISA Pair in an In Vitro Pharmacokinetic Pharmacodynamic PKPD Model J. Werth

87 MONDAY SCIENTIFIC SESSIONS Final Program A-612 Comparison of Vancomycin Dosing in Normal Body Habitus, Overweight, and Obese Pediatric Patients

M. P. Nelson

1,2 , D. E. Heble 2 , D. A. Hunstad 3 ; 1 Southern Illinois Univ. Edwardsville, Edwardsville, IL, 2 St. Louis Children’s Hosp., St. Louis, MO, 3 Washington Univ., St. Louis, MO. A-613 Comparing Outpatient Parenteral Antimicrobial Therapy OPAT for Methicillin-Sensitive Staphylococcus aureus MSSA Infection Using an In Vitro Pharmacodynamic Model IPDM

H. Iacovides, C. Huang, S. Zelenitsky; Univ. of Manitoba, Winnipeg, Canada.

A-614 Predictive Performance of Pharmacokinetic Models of Outpa- tients Receiving Vancomycin Continuous Infusions

T. M. Ng

1 , W. P. Lim 1 , M. Chan 1 , D. C. Lye 1 , V. H. Tam 2 ; 1 Tan Tock Seng Hosp., Singapore, Singapore, 2 Univ. of Houston, Houston, TX. A-615 Vancomycin Dose and Duration of Therapy as Risk Factors for Nephrotoxicity in Adult Patients

J. Brown

1 , V. Stevens 1 , K. Brown 2 , N. Onufrak 1 ; 1 SUNY Buffalo Sch. of Pharmacy and Pharmaceutical Sci., Buffalo, NY, 2 Univ. of Rochester Med. Ctr., Rochester, NY. A-616 Vancomycin Nephrotoxicity With or Without Administration of Intravenous Contrast Media

A. Lee

1 , J. Joo 2 , A. Jeng 2 , P. Chan 1 ; 1 Western Univ. of Hlth. Sci., Pomona, CA, 2 Olive View-UCLA Med. Ctr., Sylmar, CA. A-617 Average 24-Hour Area Under the Vancomycin V Serum Concentration-Time Curve AUC, Degree of Nephrotoxicity NT, and Need for Dialysis

V. Stevens

1 , N. Onufrak 1 , K. Brown 2 , J. Brown 1 ; 1 SUNY Buffalo Sch. of Pharmacy and Pharmaceutical Sci., Buffalo, NY, 2 Univ. of Rochester Med. Ctr., Rochester, NY. A-618 Weight-Based Maintenance Dosing of Vancomycin in Hemodialysis D. Ezdon 1 , M. Brown 1,2 , M. Meshay 1 , A. Brophy 1,3 , R. Hickey 1,4 , S. Aggarwal 1,5 , R. Polisetty 1,6 , B. Cuhaci 5 , J. Mitchell 1 , H. P. Schlecht 1,5 ; 1 Hahnemann Univ. Hosp., Philadelphia, PA, 2 Nanticoke Mem. Hosp., Seaford, DE, 3 Mercy St. Vincent Med. Ctr., Toledo, OH, 4 Hosp. of the Univ. of Pennsylvania, Philadelphia, PA, 5 Drexel Univ. Coll. of Med., Philadelphia, PA, 6 Midwestern Univ., Chicago Coll. of Pharmacy, Downers Grove, IL. A-619 Pharmacokinetics of Vancomycin in Patients Undergoing Continuous Venovenous Hemodialysis G. P. Mascara 1 , R. Simpson 1 , R. L. McGill 1,2 , N. H. Chan-Tompkins 1 ; 1 Allegheny Gen. Hosp., Pittsburgh, PA, 2 Drexel Univ. Coll. of Med., Pittsburgh, PA. A-620 PharmacokineticPharmacodynamic PKPD Evaluation of Oritavancin ORI against Staphylococcus aureus SA Using Data from a Murine-Thigh Infection Model O. O. Okusanya 1 , D. Lehoux 2 , A. Forrest 1 , G. Moeck 2 , C. C. Bulik 1 , P. G. Ambrose 1 , S. M. Bhavnani 1 ; 1 ICPD, Latham, NY, 2 The Med. Company, St. Laurent, Canada. A-621 Effect of Telavancin TEL and Vancomycin VAN Clearance on Staphylococcus aureus Activity in an In Vitro Pharmacokinetic Pharmacodynamic PKPD Model of Varying Renal Function

W. Rose

1 , T. Liebenstein 2 , C. Vandevoorde 1 ; 1 Univ. of Wisconsin, Madison, WI, 2 Univ. of Wisconsin Hosp. and Clinics, Madison, WI. A-622 Comparative Activity of Telavancin TLV Combined with Nafcillin NAF, Imipenem IMP, and Gentamicin GEN against Staphylococcus aureus in an In Vitro Pharmacokinetic Pharmacodynamic PKPD Model

S. N. Leonard

1,2 , M. E. Supple 1 ; 1 Northeastern Univ., Boston, MA, 2 Brigham and Women’s Hosp., Boston, MA. A-623 A Single-Center, Randomized, Placebo- and Positive-Con- trolled, Parallel-Group Study of the Electrocardiographic Effects of Dalbavancin in Healthy Male and Female Subjects

M. Dunne

1 , S. R. Moriarty 1 , C. R. Sprenger 2 ; 1 Durata Therapeutics, Mor- ristown, NJ, 2 Cetero Res., Fargo, ND. ------------------------------------------------------------------------ 083A Poster Session Improving Pharmacodynamics of Beta-Lactams and Beta-Lactamase Inhibitors Monday, 11:15 a.m.–1:15 p.m. . . . . . . . . . . . . . . . . . . . Halls A-C Presentations: A-624 fTMIC Predicts Probability of Microbiological Outcome in the Treatment of Nosocomial Pneumonia by Ceftobiprole

A. E. Muller

1 , N. Punt 2 , J. W. Mouton 1 ; 1 UMC St Radboud, Nijmegen, Netherlands, 2 Medimatics, Maastricht, Netherlands. A-624a Monte Carlo Simulations Based on Phase 1 Studies Predict Target Attainment of Ceftobiprole in Nosocomial Pneumonia Patients: A Validation Study

A. Muller

1 , A. H. Schmitt-Hoffmann 2 , N. Punt 3 , J. W. Mouton; 1 UMC St Radboud, Nijmegen, Netherlands, 2 Basilea Pharmaceutica Intl. Ltd, Basel, CH, Basel, Switzerland, 3 Medimatics, Maastricht, Netherlands. A-625 Efficacy of Ceftaroline Fosamil in the Staphylococcal Murine Pneumonia Model A. A. Bhalodi 1 , J. L. Crandon 1 , D. Biek 2 , D. P. Nicolau 1 ; 1 Ctr. for Anti-In- fect. Res. Dev., Hartford Hosp., Hartford, CT, 2 Cerexa, Inc., Oakland, CA. A-626 An Evaluation of Ceftaroline CPT and Daptomycin DAP or Vancomycin VAN Combination against an Isogenic Methi- cillin-Resistant Staphylococcus aureus MRSA Vancomycin In- termediate

S. aureus VISA Pair in an In Vitro Pharmacokinetic Pharmacodynamic PKPD Model

B. J. Werth

1 , G. Sakoulas 2 , W. E. Rose 3 , M. J. Rybak 1 ; 1 Anti-Infective Res. Lab., Wayne State Univ, Detroit, MI, 2 Univ. of California, La Jolla, CA, 3 Univ. of Wisconsin-Madison, Madison, WI. A-627 Evaluation of Ceftaroline CPT Activity against Heterore- sistant Vancomycin Intermediate Staphylococcus aureus hVISA and VISA Methicillin-Resistant

S. aureus MRSA Strains in an In Vitro PharmacokineticPharmacodynamicPKPD Model: